ELTX — Elicio Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $195.92m
- $186.76m
Annual cashflow statement for Elicio Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -54.6 | -38.8 | -35.2 | -51.9 | -39.6 |
| Depreciation | |||||
| Non-Cash Items | 27.8 | 4.47 | 2.18 | 10.6 | 5.86 |
| Unusual Items | |||||
| Equity in Net Earnings/Losses | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -26 | -4.23 | -0.057 | 3.96 | -3.44 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Net Change in Other Assets & Liabilities | |||||
| Cash from Operating Activities | -52.6 | -38.4 | -32.7 | -37.1 | -37 |
| Capital Expenditures | -0.382 | 0 | -0.066 | -0.087 | -0.016 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | — | — | 0.034 | 0.003 | 0 |
| Sale of Fixed Assets | |||||
| Cash from Investing Activities | -0.382 | 0 | -0.032 | -0.084 | -0.016 |
| Financing Cash Flow Items | 107 | -0.002 | 21.6 | -0.549 | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 107 | -0.06 | 38.6 | 42.3 | 36.7 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 54.1 | -38.3 | 5.89 | 5.19 | -0.225 |